Top 5 Stock Picks of Eli Casdin’s Casdin Capital

In this article, we discuss the top 5 stock picks of Eli Casdin’s Casdin Capital. If you want to read our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 10 Stock Picks of Eli Casdin’s Casdin Capital.

5. MaxCyte, Inc. (NASDAQ:MXCT)

Casdin Capital’s Stake Value: $66,084,000
Percentage of Casdin Capital’s 13F Portfolio: 5.58%
Number of Hedge Fund Holders: 10

MaxCyte, Inc. (NASDAQ:MXCT), a worldwide life sciences company, is involved in the research, development, and commercialization of novel cell therapies. Following MaxCyte, Inc. (NASDAQ:MXCT)’s “beat and raise” Q2 report on August 14, BTIG analyst Mark Massaro increased his price target on the stock to $11 from $10 and maintained a ‘Buy’ rating on the shares.

Comprising of 13.97 million shares, Casdin Capital’s stake in MaxCyte, Inc. (NASDAQ:MXCT) at the end of the second quarter was worth $66.08 million. The stock accounts for 5.58% of the fund’s total 13F portfolio. Out of the hedge funds being tracked by Insider Monkey, New York-based investment firm Casdin Capital is the leading shareholder of MaxCyte, Inc. (NASDAQ:MXCT).

According to Insider Monkey’s data, 10 hedge funds were long MaxCyte, Inc. (NASDAQ:MXCT) at the end of Q2 2022, compared to 12 funds in the prior quarter.

Here is what Baron Funds, an asset management firm, had to say about MaxCyte, Inc. (NASDAQ:MXCT) in its Q2 2022 investor letter:

“During the quarter, we exited MaxCyte, Inc., an early-stage cell and gene therapy tools company, whose value largely depends on milestone payments and commercialized product revenues of its customers.”